Literature DB >> 497341

A multiple testing procedure for clinical trials.

P C O'Brien, T R Fleming.   

Abstract

A multiple testing procedure is proposed for comparing two treatments when response to treatment is both dichotomous (i.e., success or failure) and immediate. The proposed test statistic for each test is the usual (Pearson) chi-square statistic based on all data collected to that point. The maximum number (N) of tests and the number (m1 + m2) of observations collected between successive tests is fixed in advance. The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations. The power is also found to be virtually the same. However, by affording the opportunity to terminate early when one treatment performs markedly better than the other, the multiple testing procedure may eliminate the ethical dilemmas that often accompany clinical trials.

Entities:  

Mesh:

Year:  1979        PMID: 497341

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  573 in total

1.  The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1.

Authors: 
Journal:  Control Clin Trials       Date:  1999-12

Review 2.  [Monitoring of clinical trials. Methodology, interim analyses, and end results].

Authors:  M Pritsch; K Unnebrink
Journal:  Med Klin (Munich)       Date:  1999-12-15

3.  Assessing effects on long-term survival after early termination of randomized trials.

Authors:  Y Shen; T R Fleming
Journal:  Lifetime Data Anal       Date:  1999       Impact factor: 1.588

4.  Optimized group sequential study designs for tests of genetic linkage and association in complex diseases.

Authors:  I R König; H Schäfer; H H Müller; A Ziegler
Journal:  Am J Hum Genet       Date:  2001-07-26       Impact factor: 11.025

5.  Interim analyses and sequential designs in phase III studies.

Authors:  S Todd; A Whitehead; N Stallard; J Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 6.  Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

Authors:  C T Yiannoutsos; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

7.  Group sequential methods and sample size savings in biomarker-disease association studies.

Authors:  R Aplenc; H Zhao; T R Rebbeck; K J Propert
Journal:  Genetics       Date:  2003-03       Impact factor: 4.562

8.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

9.  Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

Authors:  F Stephen Hodi; Sandra Lee; David F McDermott; Uma N Rao; Lisa H Butterfield; Ahmad A Tarhini; Philip Leming; Igor Puzanov; Donghoon Shin; John M Kirkwood
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

10.  Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

Authors:  J L Lefebvre; F Rolland; M Tesselaar; E Bardet; C R Leemans; L Geoffrois; P Hupperets; L Barzan; D de Raucourt; D Chevalier; L Licitra; F Lunghi; R Stupp; D Lacombe; J Bogaerts; J C Horiot; J Bernier; J B Vermorken
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.